Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy Volunteers (Meningococcal Infection)

Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

CompletedNCT03691610

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-04End: 2023-10-20Updated: 2024-06-25

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

CompletedNCT03869866

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2019-04-09End: 2022-03-18Updated: 2025-03-17

Related Papers

Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6–23 months: phase III study (US/Puerto Rico)

Pediatric Research2026-03-06

Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study.

2026-01-28

P-662. Phase III, modified double-blind, randomized, parallel group, active-controlled, multi-center study of Meningococcal quadrivalent ACWY conjugated vaccine in infants from 6 through 23 months of age in the United States

Open Forum Infectious Diseases2025-01-29